Case Study Package 2 - HUB Organoids

OVERVIEW

Our client faced uncertainty in determining whether gastrointestinal toxicity observed in dogs would translate to humans, as similar toxicity was not observed in rats. Through organoid-based screening across human and animal models, we confirmed that the toxicity profile in dog organoids aligned closely with human data, allowing the client to move forward with a clear therapeutic window.

THE CHALLENGE

Our client’s in vivo testing results showed gastrointestinal (GI) toxicity in non-rodent species dogs, but not a similar profile in rats, making it unclear if the toxicity would be relevant to human outcomes in future trials. To progress, they needed to determine whether this toxicity profile in dogs would translate to humans.

THE STRATEGY

To clarify the compound’s toxicity potential, we conducted an in vitro screening using organoids derived from human, dog, mini-pig, and rat tissues. Each organoid model was carefully selected to match the client’s needs for relevant GI toxicity markers, and our team designed a screen that allowed precise comparisons of toxicity profiles across species.

Here is what our clients have to say

When we invest heavily in a lead compound and encounter discordant toxicity in animal studies, it’s invaluable to verify if that toxicity translates to humans. The organoid testing provided a reliable cross-check at only a fraction of the cost, helping us make more confident, data-backed decisions.

– Head Translational Science, Pharma*

*anonymized to protect the confidentiality of the client

THE RESULTS

The data showed that the dog organoids exhibited toxicity patterns that closely matched those of human organoids, while the rat organoids did not align with human results. Armed with this insight, our client identified a potential therapeutic window and gained confidence that their drug’s GI toxicity in dogs would likely translate to humans, guiding them in refining their preclinical strategy